Calls
1
u/a_moron_in_a_hurry
Reddit r/biotech_stocks
Win Rate
0.0%
return
-1.6%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 14
$41.21
-1.6%
The author argues Veracyte's $150M cash purchase of Convergent Genomics (plus up to $30M in milestones) is a good move, with the UroAmp urine-based tumor DNA bladder cancer test as the key asset. The mechanism is that if Veracyte can scale UroAmp and secure wider adoption and reimbursement, it becomes a meaningful new growth driver for the company. The author states they are more bullish on VCYT after the deal, with no explicit time horizon given. The main stated risk is whether they overpaid for the acquisition.
Construction & Infrastructure
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/a_moron_in_a_hurry has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026. Most covered: VCYT.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
